QurieGen
Utilizing a high-throughput proprietary approach for mapping cellular responses, combined with single-cell genomics and data science, to craft predictive models of disease biology and drug response.
| Date | Investors | Amount | Round |
|---|---|---|---|
* | €2.2m | Seed | |
| Total Funding | 000k | ||
Related Content
QurieGen, established in April 2022 as a spin-off from Radboud University, is a biotechnology firm focused on advancing drug discovery. The company aims to address the limitations of conventional analytical tools, which often provide an incomplete understanding of cellular responses to drug candidates.
QurieGen has developed a proprietary technology that maps cellular reactions to drug stimuli. This method provides a comprehensive view of signaling pathways by simultaneously quantifying mRNA molecules, membrane proteins, and intracellular proteins. The firm is also building an AI-driven platform to predict these cellular responses, facilitating a more data-centric approach to drug discovery.
By offering a clearer and more complete picture of a drug's effects at the cellular level, QurieGen supports pharmaceutical companies in the early identification of promising drug molecules. This has the potential to shorten development timelines and reduce the costs associated with bringing new drugs to market. The company operates on a business-to-business model, providing its specialized services to clients in the pharmaceutical industry.
To fund its growth and the development of its AI platform, QurieGen has secured EUR 2.2 million in a pre-seed funding round.
Keywords: drug discovery, biotechnology, cellular analysis, AI platform, pharmaceutical services, signaling pathways, mRNA quantification, pre-seed funding, Radboud University spin-off, drug development